{
    "clinical_study": {
        "@rank": "58876", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "ATX-101", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to explore the safety and efficacy of subcutaneous\n      injections of ATX-101  relative to placebo, in the submental area of subjects who are 65 to\n      75 years old."
        }, 
        "brief_title": "Safety Study of ATX-101 for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Submental Fat", 
            "Healthy Volunteers"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, 65 to 75 years of age\n\n          -  Stable Body Weight\n\n          -  Dissatisfaction with the submental area expressed by subject\n\n          -  Acceptable volume of submental fat graded by clinician\n\n          -  BMI of \u226440.0 kg/m2\n\n          -  Signed informed consent (ICF)\n\n        Exclusion Criteria:\n\n          -  No prior intervention for SMF (eg liposuction, surgery or lipolytic agents)\n\n          -  Absence of clinically significant health problems\n\n          -  History of any intervention to treat SMF (eg liposuction, surgery, or lipolytic\n             agents)\n\n          -  Anatomical features for which reduction in SMF may result in aesthetically\n             unacceptable outcome, judged by clinician\n\n          -  History of trauma associated with the chin or neck areas  that in the judgment of the\n             investigator may affect evaluation of safety or efficacy\n\n          -  Body mass index of \u2264 40.0 kg/m2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123134", 
            "org_study_id": "ATX-101-13-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "ATX-101", 
                "intervention_name": "ATX-101", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35205"
                    }, 
                    "name": "Gary Monheit, M.D."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Pearl Grimes"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34209"
                    }, 
                    "name": "Susan Weinkle"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Metairie", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70006"
                    }, 
                    "name": "William Coleman, M.D."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "White Plains", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10604"
                    }, 
                    "name": "Rhoda Narins, M.D."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45255"
                    }, 
                    "name": "Robert Fixler, M.D."
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age", 
        "other_outcome": [
            {
                "description": "PK parameters will include area under the concentration time curve (AUC) from time zero to 24 hours, time to maximum concentration (tmax), maximum observed plasma concentration (Cmax) for both ATX-101 and placebo treated subjects.", 
                "measure": "PK plasma parameters following ATX-101 or placebo administration in a subset of subjects", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 15, 30, 45, 60, and 90 minutes, and 2, 4, 8, 12 and 24 hrs"
            }, 
            {
                "measure": "Determination of deoxycholate plasma concentration in subset of subjects", 
                "safety_issue": "No", 
                "time_frame": "pre dose, week 16 OR week 24"
            }, 
            {
                "measure": "Safety and tolerability as assessed by treatment area evaluations", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Safety and tolerability as assessed by concomitant medications", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Safety and tolerability as assessed by clinical laboratory evaluations", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Safety and tolerability as assessed by vital sign measurements", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Safety and tolerability as assessed by physical examinations", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Efficacy assessments on submental fat using calipers", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Efficacy assessments using standardized photography", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }
        ], 
        "overall_contact": {
            "email": "adavis@clinicalsiteservices.com", 
            "last_name": "Amy Davis", 
            "phone": "1-877-284-1213"
        }, 
        "overall_official": {
            "affiliation": "Sponsor GmbH", 
            "last_name": "Frederick Beddingfield, III, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability as assessed by adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 32 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123134"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy assessments using a clinician rating scale", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Efficacy assessments using patient reported scales", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }, 
            {
                "measure": "Efficacy assessments using a laxity scale", 
                "safety_issue": "No", 
                "time_frame": "up to 32 weeks"
            }
        ], 
        "source": "Kythera Biopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kythera Biopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}